Renal damage in HIV infection


Cite item

Full Text

References

  1. Белозеров Е. С., Буланьков Ю. И. ВИЧ-инфекция. Элиста: АПП "Джангар"; 2006.
  2. Gupta S. К., Eustace J. A., Winston J. A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America . Clin. Infect. Dis. 2005; 40: 1559-1585.
  3. Gupta S. K., Mamlin B. W., Johnson C. S. et al. Prevalence of proteinuria and development of chronic kidney disease in HIV-infected patients. Clin. Nephrol. 2004; 61: 1-6.
  4. Szczech L. A., Gupta S. K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66: 1145-1152.
  5. Röling J., Schmid H., Fischereder M. et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin. Infect. Dis. 2006; 42: 1488-1495.
  6. Kimmel P. L., Barisoni L., Kopp J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003; 139: 214-227.
  7. Winston J. A., Klotman M. E., Klotman P. E. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int. 1999; 55: 1036-1040.
  8. Atta M. G., Choi M. J., Longenecker J. С. et. al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am. J. Med. 2005; 118: 1288.
  9. Rao T. K., Filippone E. J., Nicastri A. D. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1984; 310 (11): 669- 673.
  10. D'Agati V., Appel G. B. HIV infection and the kidney. J. Am. Soc. Nephrol. 1997; 8: 138-152.
  11. United States Renal Data System 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 2003.
  12. Lucas G. M., Eustace J. A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18 (3): 541-546.
  13. Abbott K. C., Hypolite L., Welch P. G., Agodoa L. Y. Human immunodeficiency virus/acquired immunodeficiency syndromeassociated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the prehighly active antiretroviral therapy era. J. Nephrol. 2001; 14 (5): 377-383.
  14. Woolley I. J., Kalayjian R., Valdez H. et al. HIV nephropathy and the Duffy antigen/receptor for Chemokines in African Americans. J. Nephrol. 2001; 14: 384-387.
  15. Pardo V., Meneses R., Ossa L. et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int. 1987; 31 (5): 1167-1173.
  16. Monahan M., Tanji N., Klotman P. E. HIV-associated nephropathy: an urban epidemic. Semin. Nephrol. 2001; 21: 394- 402.
  17. Laradi A., Mallet A., Beaufils H. et al. HIV-associated nephropathy: outcome and prognosis factors. J. Am. Soc. Nephrol. 1998; 9: 2327-2335.
  18. Bruggeman L. A., Dikman S., Meng С. et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 1997; 100 (1): 84-92.
  19. Winston J. A., Bruggeman L. A., Ross M. D. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 2001; 344 (26): 1979- 1984.
  20. Marras D., Bruggeman L. A., Gao F. et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 2002; 8 (5): 522-526.
  21. Han T. M., Naicker S., Ramdial P. K. et al. A cross-sectional study of HIV-seropozitive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006; 69 (12): 2243- 2250.
  22. Ross M. J., Bruggeman L. A., Wilson P. D., Klotman P. E. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2001; 12: 2645-2651.
  23. Husain M., Gusella G. L., Klotman M. E. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 2002; 13 (7): 1806-1815.
  24. Ting-chi L., Ross M. HIV-associated nephropathy: a brief review. Mount Sinai J. Med. 2005; 75 (3): 193-199.
  25. Ahmed S., Siddiqui R. K., Siddiqui A. K. et al. HIV associated thrombotic microangiopathy. Postgrad. Med. J. 2002; 78: 520-524.
  26. Mientjes G., van Amerijden E., Mulder J. W. et al. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br. J. Haematol. 1992; 82: 615-619.
  27. Sutor G. C., Schmidt R. E., Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of literature. Infection. 1999; 27: 12-15.
  28. Vyakarnam A., Meatar P., Meager A. et al. Altered production of tumor necrosis factor alpha and beta and interferon gamma by HIV-infected individuals. Clin. Exp. Immunol. 1991; 84: 109-115.
  29. Sahud M. A., Clater S., Liu L. et al. von Willenrad factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br. J. Haematol. 2002; 116: 909-911.
  30. Bell W. R., Chulay J. D., Feinberg J. E. Manifestations resembeling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76: 369-380.
  31. Weiner N. J., Goodman J. W., Kimmel P. L. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int. 2003; 63: 1618-1631.
  32. Kimmel P. L., Barisoni L., Kopp J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003; 139: 214-227.
  33. Horvath J., Raffanti S. P. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin. Infect. Dis. 1994; 18 (3): 339-347.
  34. Beaufils H., Jouanneau C., Katlama C. et al. HIV-associated IgA nephropathy: a post-mortem study. Nephrol. Dial. Transplant. 995; 10: 35-38.
  35. Nochy D., Glotz D., Dosquet P. et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol. Dial. Transplant. 1993; 8: 11-19.
  36. Humphreys M. H. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int. 1995; 48: 311.
  37. Kimmel P. L., Phillips Т. М., Ferreira-Centeno A. et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N. Engl. J. Med. 1992; 327: 702-706.
  38. Haas M., Kaul S., Eustace J. A. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinocopathological study of 14 cases. Kidney Int. 2005; 67: 1381- 1390.
  39. Franceschini N., Napravnik S., Eron J. J. et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005; 67: 1526-1531.
  40. Dong B. J., Rodriguez R. A., Goldschmidt R. H. Sulfadiazine-induced crystalluria and renal failure in a patient with AIDS. J. Am. Board Fam. Pract. 1999; 12 (3): 243-248.
  41. Berns J. S., Cohen R. M., Stumacher R. J., Rudnick M. R. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J. Am. Soc. Nephrol. 1991; 1 (9): 1061-1080.
  42. Peraldi M. N., Maslo C., Akposso K. et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999; 14: 1578-1585.
  43. Betjes M. G., Verhagen D. W. Stable improvement of renal function after initiation of highly active anti-retroviral therapy in patients with HIV-1-associated nephropathy. Nephrol. Dial. Transplant. 2002; 17: 1836-1839.
  44. Szczech L. A., Edwards L. J., Sanders L. L. et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin. Nephrol. 2002; 57: 336-341.
  45. Murphy M. D., O'Hearn M., Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis. 2003; 36: 1082-1085.
  46. Daugas E., Rougier J. P., Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005; 67: 393-403.
  47. Barbour T. D., Furlong Т. J., Finlayson R. J. Efavirenz-associated podocyte damage. AIDS 2007; 21: 257-258.
  48. Wei A., Burns G. C., Williams B. A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003; 64 (4): 1462-1471.
  49. Eustace J. A., Nuermberger E., Choi M. et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000; 58 (3): 1253-1260.
  50. Tabechian D., Pattanaik D., Suresh U. et al. Lupus-like nephritis in an HIV-positive patient: report of a case and review of the literature. Clin. Nephrol. 2003; 60: 187-194.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies